TAK1の阻害は,KRASに依存した大腸がんにおけるアポトシスを促進する
Anurag Singh1, Michael F Sweeney, Min Yu
1Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA.
Cell
|February 21, 2012
まとめ
TAK1キナーゼ (MAP3K7) をターゲットにすることで,KRAS変異性結腸がんに対する新しい治療戦略が提供されます. このキナーゼは,Wnt信号伝達を抑制することで,腫瘍細胞の生存に不可欠であり,潜在的な治療の道を示しています.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 癌の信号伝達経路について
背景:
- KRAS変異は結腸がんに多く見られるが,すべてのKRAS変異細胞が生存のためにKRAS信号伝達に依存しているわけではない.
- これらの耐性がんサブセットにおける特定の依存性を特定することは,効果的な治療法の開発に不可欠です.
研究 の 目的:
- KRASに依存する結腸がん細胞の生存に不可欠なキナーゼを特定する.
- KRAS変異性大腸がん生存率とWntシグナル伝達におけるTAK1キナーゼの役割を調査する.
主な方法:
- キナーゼスクリーニングは,KRASに依存した結腸がん細胞の生存促進キナーゼを特定するために行われます.
- RNA干渉 (RNAi) と薬理学的阻害により,TAK1の活性が低下または阻害される.
- Wnt信号活性化とアポトーシス誘導の分析.
- BMPシグナル伝達経路の評価と,TAK1の活性化との関連.
- "TAK1依存シグネチャー"の評価,ヒト大腸がんの原発性サンプル.
主要な成果:
- TAK1キナーゼ (MAP3K7) は,KRASに依存した結腸がん細胞の生存に不可欠であると特定されました.
- TAK1誘発のアポトーシスの抑制は,活性化過度のWnt信号伝達を抑制することによって行われる.
- APC変異/KRAS依存細胞におけるKRASシグナリングはBMP-7の分泌を刺激し,TAK1の活性化とWntシグナリングの強化につながります.
- "TAK1依存性シグネチャー"は,APCとKRASの両方の変異を有するヒト大腸がんで強化されました.
結論:
- TAK1キナーゼは,KRAS変異性大腸がんのサブセットにおける生存の重要な媒介である.
- TAK1抑制は,異常なKRASおよびWnt経路活性化による治療抵抗性結腸がんの潜在的な治療戦略です.
- この発見は,特定の変異に基づく患者集団の階層化における臨床的有用性を示唆しています.
関連する概念動画
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Caspases
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

